Patents for A61P 35 - Antineoplastic agents (221,099)
12/2007
12/19/2007CN101088997A Improved process of preparing Raltitrexed
12/19/2007CN101088565A Use of miRNA-34a
12/19/2007CN101088563A Anticancer composition containing lomustine
12/19/2007CN101088562A Anticancer composition containing ranimustine
12/19/2007CN101088555A Medicine prepn for inhibiting tumor angiogenesis and cancer cell and enhancing immunity
12/19/2007CN101088551A Medicine for treating diseases of liver, gall bladder and pancreas and cancer metastasis
12/19/2007CN101088541A Medicine for treating women's tumors and malignant tumors and its prepn proces
12/19/2007CN101088536A Specific medicine for treating malignant lymphomas
12/19/2007CN101088521A Astragalus medicine prepn and its prepn process
12/19/2007CN101088520A Medicine composition for auxiliary treatment of cancer and its prepn and quality control method
12/19/2007CN101088516A Chinese medicine prepn for treating leukemia
12/19/2007CN101088513A 生命技术及其应用 Life Technologies and Applications
12/19/2007CN101088502A Mixture solution containing conjugate of transferrin and quercetin and its use
12/19/2007CN101088497A Composition containing lycopane and thioglycoside
12/19/2007CN101088496A Microecological bifid bacterium signal molecule prepn and its prepn process
12/19/2007CN101088492A Stable supersaturated gemcitabine hydrochloride solution and its prepn process
12/19/2007CN101088491A Anticancer composition
12/19/2007CN101088352A Glossy ganoderma health tea making process
12/19/2007CN100355882C Hybridoma cell strain and its produced human VEGFR-3 resistant monoclonal antibody
12/19/2007CN100355786C Polyethylene glycol-modified thymus peptide 1 derivatives
12/19/2007CN100355784C Method for preparing polyethylene glycol-modified alpha-interferon 1b
12/19/2007CN100355782C New liver cancer up expressing gene and its encoded protein and application
12/19/2007CN100355781C 肽 Peptide
12/19/2007CN100355770C Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
12/19/2007CN100355751C 2-substd. 4-heteroaryl-pyrimidines and their use in treatment of proliferative disorders
12/19/2007CN100355744C Separation and extraction of flavone natural product active component for treating prostating disorders and medicinal preparation preparing and use thereof
12/19/2007CN100355458C Use of artificial proliferative inhibiting gene-adenovirus expression carrier
12/19/2007CN100355454C Nano-magnetic powder antihuman lirer cancer single anti HAb18 target medicine for magnetic heat therapy
12/19/2007CN100355423C Combination comprising a vasculostatic compound and an alkylating agent for the treatmemt of a tumor
12/19/2007CN100355422C Pharmaceutical composition containing platinum complex as active substance and method of manufacturing thereof
12/19/2007CN100355420C Leucine-enriched nutritional compositions
12/19/2007CN100355418C Magnetic nano-balls carried with cisplatin and its prepn. method
12/19/2007CN100355417C Formulation of 'Duyiwei' with improved bioavailability and drug effect and preparation process thereof
12/18/2007US7309800 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors
12/18/2007US7309760 Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
12/18/2007US7309721 Aminoalkylphosphonates and related compounds as Edg receptor agonists
12/18/2007US7309710 Crystals
12/18/2007US7309705 7-carboxamido- or sulfonamido-substituted: 2-Phenyl-3-cyclopropyl-7-(4-pyridylcarboxamido)pyrazolo[1.5a]pyrimidine; anticarcinogenic, antiinflammatory, neurodegenerative agent; arthritis, Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases; with other active compounds
12/18/2007US7309692 Inhibition of Grb2 and Crk1 gene products that interact with the bcr-abl product and participate in the transformation of Chronic myeloid leukemia
12/18/2007US7309689 Sustained peptide-release formulation
12/18/2007US7309688 Topical application of formulation containing non-denatured, soy product in a carrier for inhibiting the progression of a cutaneous tumor
12/18/2007US7309604 Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
12/18/2007US7309586 Chimeric coiled coil molecules
12/18/2007CA2436799C Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
12/18/2007CA2418479C Prodrugs of betulinic acid derivatives for the treatment of cancer
12/18/2007CA2299471C Combination of tyrosine kinase inhibitor and chemical castration to treat prostate cancer
12/18/2007CA2249390C Peptides recognized by melanoma-specific a1-, a2- and a3-restricted cytotoxic lymphocytes, and uses therefor
12/18/2007CA2219070C Methods of preventing breast cancer
12/18/2007CA2209001C Hydrophobic taxane derivatives
12/18/2007CA2062047C Fusion proteins for prodrug activation, the preparation and use thereof
12/18/2007CA1341566C Immune response to tumors induced by anti-idiotype antibodies
12/13/2007WO2007143600A2 Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
12/13/2007WO2007143582A2 Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
12/13/2007WO2007143483A2 Combination of pazopanib and lapatinib for treating cancer
12/13/2007WO2007143175A2 Combination of ceramide and oxaliplatin for inducing cell death and uses thereof in treating cancer
12/13/2007WO2007143096A2 Compounds for treating cancers
12/13/2007WO2007142973A1 Cobalamin compositions and methods for treating or preventing mucositis
12/13/2007WO2007142336A1 Gene involved in immortalization of human cancer cell and use thereof
12/13/2007WO2007142323A1 Novel indazole derivative having spiro ring structure in side chain
12/13/2007WO2007142303A1 Method for controlling the amount of gene product, and agent for controlling the amount of gene product
12/13/2007WO2007142277A1 Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
12/13/2007WO2007142241A1 Immunocompetent cell having anti-cd38 antibody on its cell surface
12/13/2007WO2007142217A1 1-phenylpyridone derivative
12/13/2007WO2007142139A1 Method of identifying candidate for remedy of acute myeloid leukemia
12/13/2007WO2007142096A1 Inhibitor of inducible nitric oxide synthase, beverage/food, and neutraceutical food
12/13/2007WO2007141533A2 Fkbp-l and uses thereof
12/13/2007WO2007141473A1 N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
12/13/2007WO2007141283A2 Salts and crystalline salt forms of an 2-indolinone derivative
12/13/2007WO2007140957A1 Sulfimides as protein kinase inhibitors
12/13/2007WO2007140924A1 Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer
12/13/2007WO2007140907A1 Use of serine endopeptidases 22 (prss22) as a therapeutic or diagnostic target
12/13/2007WO2007140667A1 A ptd-vp3 fusion protein as anti-tumor medecine and preparing process
12/13/2007WO2007140662A1 Fluoroalkyloxy-containing combretastatin derivatives, preparation and use thereof
12/13/2007WO2007140618A1 Modified protein toxins targeting cytokine -receptor bearing cells and use thereof for treating disease
12/13/2007WO2007140613A1 Fermented milk product and use thereof
12/13/2007WO2007140534A1 Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
12/13/2007WO2007120827A3 Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders
12/13/2007WO2007118660A3 Her-2/neu multi-peptide vaccine
12/13/2007WO2007116025A3 Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia
12/13/2007WO2007111904A3 C-met protein kinase inhibitors for the treatment of proliferative disorders
12/13/2007WO2007109251A3 Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
12/13/2007WO2007064797A3 Inhibitors of c-met and uses thereof
12/13/2007WO2007038171A3 Peptide nucleic acid based guanidinium compounds
12/13/2007WO2005048916A3 Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
12/13/2007US20070287970 Method for systemic drug delivery through the nail
12/13/2007US20070287826 Production of high molecular mass lectins
12/13/2007US20070287754 Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
12/13/2007US20070287745 Laulimalide Analogs and Uses Thereof
12/13/2007US20070287737 Novel heteroaryl-substituted arylaminopyridine derivatives as MEK inhibitors
12/13/2007US20070287725 Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method
12/13/2007US20070287724 Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines
12/13/2007US20070287721 Pyrazolopyridinyl pyridine
12/13/2007US20070287718 Methods for the Treatment of Multiple Myeloma Using Roscovitine
12/13/2007US20070287713 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
12/13/2007US20070287706 Certain substituted quinolones, compositions, and uses thereof
12/13/2007US20070287703 Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer
12/13/2007US20070287680 Combined Active and Passive Targeting of Biologically Active Agents
12/13/2007US20070287677 Rad51 Expression Inhibitors, Pharmaceutical Agents Containing The Inhibitors As Active Ingredients, And Uses Thereof
12/13/2007US20070287672 Macromolecular Gsh-Activiated Glyoxylase I Inhibitors
12/13/2007US20070287662 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress